Delcath Systems, Inc. (DCTH)
NASDAQ:DCTH
Want to see DCTH full AI Analyst Report?
DCTH Stock Chart & Stats
$10.86
-$0.29(-2.36%)
At close: 4:00 PM EST
$10.86
-$0.29(-2.36%)
Day’s Range― - ―
52-Week Range$8.12 - $14.18
Previous CloseN/A
Volume96.76K
Average Volume (3M)565.52K
Market Cap
$397.34M
Enterprise Value$371.44M
Total Cash (Recent Filing)$89.30M
Total Debt (Recent Filing)$907.00K
Price to Earnings (P/E)697.6
Beta1.53
Next Earnings
Aug 10, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding34,521,650
10 Day Avg. Volume672,573
30 Day Avg. Volume565,524
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)3.25
Price to Sales (P/S)4.24
P/FCF Ratio17.25
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue4.11
Enterprise Value/Gross Profit4.78
Enterprise Value/Ebitda222.68
Forecast
1Y Price Target
$22.33Price Target Upside105.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.59
Revenue Forecast (FY)$103.87M
Bulls Say, Bears Say
Bulls Say
Rapid Revenue Growth & Cash GenerationThe company converted a multi-year commercial ramp into meaningful cash flow: revenue scaled sharply 2023–2025 while operating and free cash flow turned positive in the TTM. Durable cash generation improves reinvestment capacity and reduces reliance on external financing over the next 2–6 months.
Conservative Balance Sheet / Low LeverageA low-debt capital structure and a strengthened equity base provide financial flexibility to fund commercial expansion, R&D and potential M&A. High cash reserves and minimal leverage materially reduce refinancing and liquidity risk during ongoing commercialization and clinical development.
Compelling Clinical Evidence (CHOPIN)Peer-reviewed CHOPIN results showing improved PFS/OS with HEPZATO plus immunotherapy validate the platform's clinical utility. Strong published evidence supports durable physician adoption, guideline influence, and expanded use in liver-directed oncology over coming quarters.
Bears Say
Thin, Volatile Operating ProfitabilityAlthough net income is marginally positive, persistent negative TTM EBIT signals operating profitability remains fragile. Narrow and inconsistent operating margins could constrain sustainable EBITDA improvement and make earnings sensitive to volume, pricing, or cost fluctuations over the next several quarters.
Slower Site Activation And Clinical EnrollmentSlower-than-expected center activations and delayed trial enrollment lengthen commercial and clinical timelines. This dampens procedure throughput growth and delays pivotal data, creating execution risk that can impair revenue ramp and market penetration over a 2–6 month horizon.
Rising R&D And SG&A Spending PressureMaterial increases in R&D and commercial SG&A to support expansion raise operating leverage and compress near-term adjusted EBITDA. Elevated discretionary spend heightens execution risk: if revenue growth lags, margin recovery and sustained profitability could be pushed further into the future.
Delcath Systems News
DCTH FAQ
What was Delcath Systems, Inc.’s price range in the past 12 months?
Delcath Systems, Inc. lowest stock price was $8.12 and its highest was $14.18 in the past 12 months.
What is Delcath Systems, Inc.’s market cap?
Delcath Systems, Inc.’s market cap is $397.34M.
When is Delcath Systems, Inc.’s upcoming earnings report date?
Delcath Systems, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 48 days.
How were Delcath Systems, Inc.’s earnings last quarter?
Delcath Systems, Inc. released its earnings results on May 07, 2026. The company reported -$0.03 earnings per share for the quarter, beating the consensus estimate of -$0.097 by $0.067.
Is Delcath Systems, Inc. overvalued?
According to Wall Street analysts Delcath Systems, Inc.’s price is currently Undervalued.
Does Delcath Systems, Inc. pay dividends?
Delcath Systems, Inc. does not currently pay dividends.
What is Delcath Systems, Inc.’s EPS estimate?
Delcath Systems, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Delcath Systems, Inc. have?
Delcath Systems, Inc. has 34,521,650 shares outstanding.
What happened to Delcath Systems, Inc.’s price movement after its last earnings report?
Delcath Systems, Inc. reported an EPS of -$0.03 in its last earnings report, beating expectations of -$0.097. Following the earnings report the stock price went down -0.178%.
Which hedge fund is a major shareholder of Delcath Systems, Inc.?
Currently, no hedge funds are holding shares in DCTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Delcath Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.33 (105.65% Upside)
$22.33 (105.65% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 65.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.44%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
42.97%
Trailing 12-Months
Company Description
Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
DCTH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a balanced mix of positive commercial and clinical momentum (record new patient starts, robust volume growth, encouraging CHOPIN data driving adoption, solid revenue growth and strong cash balance) alongside meaningful near-term operational and financial headwinds (slower-than-expected site activations and trial enrollment, higher R&D and SG&A spend, a quarter-over-quarter decline in adjusted EBITDA and a small net loss, plus European reimbursement constraints and seasonality risks). Management remains optimistic about hitting at least $100M in revenue for 2026 and returning to positive adjusted EBITDA for the year, but several execution and enrollment risks temper the outlook.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$22.33
▲(105.65% Upside)
Technical Analysis
Ownership Overview
21.79% Insiders
7.26% Mutual Funds
24.05% Other Institutional Investors
37.86% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---